Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma

Alice Lorenzoni, Antonella Capozza, Salvatore Artale, Marco Maccauro, Ettore Cesare Seregni

Research output: Contribution to journalArticle

Abstract

Peptide receptor radionuclide therapy is an effective, well-tolerated, treatment for well-differentiated neuroendocrine tumors, resulting in a significant survival benefit and improvement of quality of life. Very few data are available on peptide receptor radionuclide therapy effectiveness in grade 3 neuroendocrine carcinomas with high somatostatin receptor expression. We report the case of a 70-year-old woman with metastatic pancreatic grade 3 neuroendocrine carcinoma who underwent 6 cycles of tandem treatment with investigational radiopharmaceuticals Y-DOTATOC and Lu-DOTATOC achieving an impressive response.

Original languageEnglish
Pages (from-to)506-508
Number of pages3
JournalClinical Nuclear Medicine
Volume43
Issue number7
DOIs
Publication statusPublished - Jul 2018

Fingerprint

Neuroendocrine Carcinoma
Peptide Receptors
Radioisotopes
Somatostatin Receptors
Investigational Therapies
Neuroendocrine Tumors
Radiopharmaceuticals
Therapeutics
Quality of Life
Survival
DOTA-Tyr(3)-90Y-octreotide
Pancreatic Carcinoma
DOTA(0)-Tyr(3)-177lu-octreotide
Edotreotide

Keywords

  • Aged
  • Carcinoma, Neuroendocrine/diagnostic imaging
  • Female
  • Humans
  • Octreotide/analogs & derivatives
  • Pancreatic Neoplasms/diagnostic imaging
  • Radiopharmaceuticals/therapeutic use

Cite this

Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma. / Lorenzoni, Alice; Capozza, Antonella; Artale, Salvatore; Maccauro, Marco; Seregni, Ettore Cesare.

In: Clinical Nuclear Medicine, Vol. 43, No. 7, 07.2018, p. 506-508.

Research output: Contribution to journalArticle

@article{effdc83eda9a450eb34839f3aab6790d,
title = "Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma",
abstract = "Peptide receptor radionuclide therapy is an effective, well-tolerated, treatment for well-differentiated neuroendocrine tumors, resulting in a significant survival benefit and improvement of quality of life. Very few data are available on peptide receptor radionuclide therapy effectiveness in grade 3 neuroendocrine carcinomas with high somatostatin receptor expression. We report the case of a 70-year-old woman with metastatic pancreatic grade 3 neuroendocrine carcinoma who underwent 6 cycles of tandem treatment with investigational radiopharmaceuticals Y-DOTATOC and Lu-DOTATOC achieving an impressive response.",
keywords = "Aged, Carcinoma, Neuroendocrine/diagnostic imaging, Female, Humans, Octreotide/analogs & derivatives, Pancreatic Neoplasms/diagnostic imaging, Radiopharmaceuticals/therapeutic use",
author = "Alice Lorenzoni and Antonella Capozza and Salvatore Artale and Marco Maccauro and Seregni, {Ettore Cesare}",
year = "2018",
month = "7",
doi = "10.1097/RLU.0000000000002116",
language = "English",
volume = "43",
pages = "506--508",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma

AU - Lorenzoni, Alice

AU - Capozza, Antonella

AU - Artale, Salvatore

AU - Maccauro, Marco

AU - Seregni, Ettore Cesare

PY - 2018/7

Y1 - 2018/7

N2 - Peptide receptor radionuclide therapy is an effective, well-tolerated, treatment for well-differentiated neuroendocrine tumors, resulting in a significant survival benefit and improvement of quality of life. Very few data are available on peptide receptor radionuclide therapy effectiveness in grade 3 neuroendocrine carcinomas with high somatostatin receptor expression. We report the case of a 70-year-old woman with metastatic pancreatic grade 3 neuroendocrine carcinoma who underwent 6 cycles of tandem treatment with investigational radiopharmaceuticals Y-DOTATOC and Lu-DOTATOC achieving an impressive response.

AB - Peptide receptor radionuclide therapy is an effective, well-tolerated, treatment for well-differentiated neuroendocrine tumors, resulting in a significant survival benefit and improvement of quality of life. Very few data are available on peptide receptor radionuclide therapy effectiveness in grade 3 neuroendocrine carcinomas with high somatostatin receptor expression. We report the case of a 70-year-old woman with metastatic pancreatic grade 3 neuroendocrine carcinoma who underwent 6 cycles of tandem treatment with investigational radiopharmaceuticals Y-DOTATOC and Lu-DOTATOC achieving an impressive response.

KW - Aged

KW - Carcinoma, Neuroendocrine/diagnostic imaging

KW - Female

KW - Humans

KW - Octreotide/analogs & derivatives

KW - Pancreatic Neoplasms/diagnostic imaging

KW - Radiopharmaceuticals/therapeutic use

U2 - 10.1097/RLU.0000000000002116

DO - 10.1097/RLU.0000000000002116

M3 - Article

VL - 43

SP - 506

EP - 508

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 7

ER -